Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

The FDA has mandated updated safety labeling for two respiratory syncytial virus vaccines, Pfizer's Abrysvo and GlaxoSmithKline's Arexvy, following the identification of an increased risk of ...

The program, which began Dec. 6 in the wake of ongoing H5N1 outbreaks at dairy farms, now includes 28 states covering 65% of the country's milk production. Other public health news is on chronic ...

RSV infections in children younger than 5 years in primary care are associated with substantial symptomatology, health-care ...

Barré for every million doses given.

The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...

Before the RSV vaccines were approved, the FDA flagged potential GBS risks with the vaccines. After approval, the CDC ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains ...

Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.